CA2884405C - Composition of hmb and atp and methods of use - Google Patents

Composition of hmb and atp and methods of use Download PDF

Info

Publication number
CA2884405C
CA2884405C CA2884405A CA2884405A CA2884405C CA 2884405 C CA2884405 C CA 2884405C CA 2884405 A CA2884405 A CA 2884405A CA 2884405 A CA2884405 A CA 2884405A CA 2884405 C CA2884405 C CA 2884405C
Authority
CA
Canada
Prior art keywords
hmb
atp
animal
composition
strength
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2884405A
Other languages
English (en)
French (fr)
Other versions
CA2884405A1 (en
Inventor
Shawn Baier
Larry KOLB
John Rathmacher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabolic Technologies LLC
Original Assignee
TSI Inc
Metabolic Technologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TSI Inc, Metabolic Technologies LLC filed Critical TSI Inc
Publication of CA2884405A1 publication Critical patent/CA2884405A1/en
Application granted granted Critical
Publication of CA2884405C publication Critical patent/CA2884405C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2884405A 2012-09-10 2013-09-10 Composition of hmb and atp and methods of use Active CA2884405C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261698919P 2012-09-10 2012-09-10
US61/698,919 2012-09-10
PCT/US2013/059039 WO2014040067A1 (en) 2012-09-10 2013-09-10 Composition of hmb and atp and methods of use

Publications (2)

Publication Number Publication Date
CA2884405A1 CA2884405A1 (en) 2014-03-13
CA2884405C true CA2884405C (en) 2021-03-30

Family

ID=50237697

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2884405A Active CA2884405C (en) 2012-09-10 2013-09-10 Composition of hmb and atp and methods of use

Country Status (14)

Country Link
US (1) US10092590B2 (https=)
EP (2) EP3733171B1 (https=)
JP (1) JP6258943B2 (https=)
CN (1) CN105025891B (https=)
AU (1) AU2013312113B2 (https=)
BR (1) BR112015005199B1 (https=)
CA (1) CA2884405C (https=)
DK (1) DK3733171T3 (https=)
ES (1) ES2970283T3 (https=)
FI (1) FI3733171T3 (https=)
HU (1) HUE065064T2 (https=)
PL (1) PL3733171T3 (https=)
PT (1) PT3733171T (https=)
WO (1) WO2014040067A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017205673A1 (en) * 2016-05-25 2017-11-30 TSI Group Ltd. Stabilization of beta-hydroxyisovaleric acid formulations in soft gel capsules
US10888576B2 (en) * 2018-10-08 2021-01-12 Metabolic Technologies, Inc. Composition of HMB and ATP and methods of use
JP2024524288A (ja) * 2021-06-22 2024-07-05 ティエスアイ ユーエスエイ エルエルシー アデノシン三リン酸（ａｔｐ）を含む組成物および認知機能に対する使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028440A (en) 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
US4992470A (en) 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals
ES2142353T3 (es) 1992-09-16 2000-04-16 Univ Iowa State Res Found Inc Procedimiento para reducir los niveles de colesterol total y de colesterol asociado a lipoproteinas de baja densidad en sangre.
US5348979A (en) 1992-12-23 1994-09-20 Iowa State University Research Foundation Inc. Method of promoting nitrogen retention in humans
US6031000A (en) 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
JP4010390B2 (ja) 1999-09-20 2007-11-21 明治乳業株式会社 免疫賦活化組成物
US7629329B2 (en) * 2001-06-04 2009-12-08 Tsi Health Sciences, Inc. Method for increasing muscle mass and strength through administration of adenosine triphosphate
US20050027005A1 (en) 2003-08-02 2005-02-03 Matthias Boldt Nutrient compositions and methods for sustenance and promotion of positive metabolic energy levels in a targeted manner
US20050215640A1 (en) * 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
US20060083793A1 (en) * 2004-09-29 2006-04-20 Gardiner Paul T Nutritional composition for promoting muscle performance and acting as hydrogen (H+) blocker
US20060073891A1 (en) * 2004-10-01 2006-04-06 Holt Timothy M Display with multiple user privacy
JP5032310B2 (ja) * 2005-05-27 2012-09-26 興和株式会社 疲労回復のための医薬
WO2007108071A1 (ja) * 2006-03-17 2007-09-27 Pharma Foods International Co., Ltd. 抗ストレス組成物及びそれを含有する飲食品
WO2010068696A1 (en) 2008-12-09 2010-06-17 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
DE102009052640A1 (de) 2009-11-10 2011-05-12 Linde-Lkca-Dresden Gmbh Verfahren und Vorrichtung zur Gaswäsche
EP2512236B1 (en) * 2009-12-18 2016-10-19 Metabolic Technologies, Inc. Improved method of administering beta-hydroxy-beta-methylbutyrate (hmb)

Also Published As

Publication number Publication date
AU2013312113A1 (en) 2015-03-26
US20140080781A1 (en) 2014-03-20
CN105025891A (zh) 2015-11-04
HK1217087A1 (zh) 2016-12-23
JP6258943B2 (ja) 2018-01-10
CA2884405A1 (en) 2014-03-13
AU2013312113B2 (en) 2018-08-02
DK3733171T3 (da) 2024-01-29
EP2892522A1 (en) 2015-07-15
CN105025891B (zh) 2020-01-21
EP2892522A4 (en) 2016-01-20
HUE065064T2 (hu) 2024-05-28
EP3733171B1 (en) 2023-10-25
JP2015527408A (ja) 2015-09-17
ES2970283T3 (es) 2024-05-27
BR112015005199A2 (pt) 2017-07-04
US10092590B2 (en) 2018-10-09
EP3733171A1 (en) 2020-11-04
PT3733171T (pt) 2024-01-31
FI3733171T3 (fi) 2024-01-24
BR112015005199B1 (pt) 2022-09-06
PL3733171T3 (pl) 2024-03-18
WO2014040067A1 (en) 2014-03-13

Similar Documents

Publication Publication Date Title
Varanoske et al. Effects of β-alanine supplementation and intramuscular carnosine content on exercise performance and health
Fitschen et al. Efficacy of β-hydroxy-β-methylbutyrate supplementation in elderly and clinical populations
JP5762396B2 (ja) 糖尿病療法の支援のためのα−ケト酸を含有する栄養補助剤
DK2512236T3 (en) IMPROVED PROCEDURE FOR ADMINISTRATION OF BETA-HYDROXY-BETA-METHYL BUTYRATE (HMB)
US20190209501A1 (en) Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (hmb) assosiated with intermittent fasting
US20160303176A1 (en) Nutritional supplement
CA2884405C (en) Composition of hmb and atp and methods of use
US20150366901A1 (en) Methods of Treating Heart Failure
US10888576B2 (en) Composition of HMB and ATP and methods of use
McDonough Oral creatine hydrochloride supplementation: acute effects on submaximal, intermittent bouts of bench press and vertical jump exercises
HK1217087B (zh) Hmb和atp的组合物及使用方法
Turpin Therapeutic role of dietary nitrates on cardiorespiratory function in cancer survivors
Kawecka et al. Creatine supplementation: facts and myths
US20240299435A1 (en) Compositions containing adenosine triphosphate (atp) and methods of use for cognitive function
Osmond The Effects of Leucine-Enriched Branched-Chain Amino Acid Supplementation on Exercise-Induced Skeletal Muscle Damage
Arney Mechanisms of Fatigability in Individuals With Prediabetes and the Effect of Dietary Nitrate Supplementation
Boyle Effects of Chronic Ingestion of L-arginine alpha ketoglutarate Combined With Creatine monohydrate on Anaerobic Performance in Strength-Trained Athletes
Fitschen Efficacy of beta-hydroxy-beta-methylbutyrate (HMB) supplementation in hemodialysis patients
Demaison et al. Is there an ‘obesity paradox’of cardiac survival in heart disease? A perspective from experimental laboratory studies
Sakkas et al. Creatine Fails to Augment the Benefits from Resistance Training in Patients with HIV
Porcelli Functional evaluation of muscle oxidative metabolism in metabolic myophaties. A cross-talk between exercise physiology and clinical medicine
Machin The effects of polyphenol supplementation on muscular strength, power, and soreness following eccentric exercise
Hogwood et al. Sex Differences in the Effects of Inorganic Nitrate Supplementation On Exercise Economy 1 and Endurance Capacity in Healthy Young Adults 2
FROST III RECOVERY DYNAMICS IN MASTER AND AGED ATHLETES
Villanueva Influence of rest interval length in between sets on hormonal responses and changes in body composition, muscular strength, and functional performance during twelve weeks of periodized resistance training in older men

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180405

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240905

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240905

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240905

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250908

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250908